A carregar...
Ad-p53 enhances the sensitivity of triple-negative breast cancer MDA-MB-468 cells to the EGFR inhibitor gefitinib
Triple-negative breast cancer (TNBC) accounts for 20% of all molecular subtypes of breast cancer. Neither endocrine nor anti-HER2 molecular targeting treatment yield promising results. At present, epidermal growth factor receptor (EGFR) inhibitor, as a single agent, is unable to obtain encouraging r...
Na minha lista:
| Publicado no: | Oncol Rep |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
D.A. Spandidos
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4306269/ https://ncbi.nlm.nih.gov/pubmed/25501339 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/or.2014.3665 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|